Drugs / Tdap
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07097012 Comparator | Oct 2025 → Jul 2026 overdue | respiratory syncytial virus infectious disease | Canadian Immunization Research Network | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07097012 ↗ |
| Modality | Vaccine | “The Tdap vaccine will be administered according to the Product Monograph.” NCT07097012 ↗ |